eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases.
Location: Belgium, Antwerp, Niel
Employees: 51-200
Total raised: $38.86M
Founded date: 2013
Investors 3
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
| - | Fund+ | fundplus.b... |
| - | Life Scien... | lspvc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.08.2022 | - | $38.86M | - |
Mentions in press and media 9
| Date | Title | Description |
| 10.07.2024 | Antonin (Tony) de Fougerolles appointed as new Chair of etherna | Brings foundational experience in mRNA and LNP therapeutics given prior executive leadership roles at Moderna & Alnylam Will take an active role in expanding partnerships with biopharma Integrated partnership offering to customers remai... |
| 27.08.2022 | eTheRNA Raises €39M in Series B2 Financing | eTheRNA, a Niel, Belgium-based mRNA technologies company, raised €39M in a Series B2 financing. The round was led by Novalis LifeSciences with participation from Professor Kenneth Chien, an expert in mRNA technology and its therapeutic appl... |
| 03.02.2022 | eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement | Partnership Press Release |
| 18.01.2022 | 4basebio Plc - Strategic Research Collaboration | 18 January 2022 4basebio PLC ("4basebio", the "Company" or the “Group”) Strategic Research Collaboration evaluating linear DNA for mRNA production 4basebio PLC (AIM: 4BB), the specialist life sciences group focused on ex... |
| 16.06.2020 | ETheRNA nabs €34M for mRNA vaccines—including COVID-19 candidate | Belgium’s eTheRNA picked up €34 million ($38 million) to bankroll the development of its mRNA technologies as well as a suite of mRNA immunotherapies for cancer and infectious diseases, including a program against SARS-CoV-2, the virus that... |
| 16.06.2020 | eTheRNA Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept | - |
| 16.06.2020 | eTheRNA : Raises EUR 34 Million in Series B Financing to Accelerate Multiple mRNA Therapeutic Development Programs Through to Clinical Proof of Concept | NIEL, Belgium, June 16, 2020 /PRNewswire/ -- eTheRNA immunotherapies NV ('eTheRNA' or 'The Company'), a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious d... |
| 16.06.2020 | eTheRNA Raises €34M in Series B Financing | eTheRNA immunotherapies, a Niel, Belgium-based clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, raised Euro €34m in a Series B equity financing ... |
| 15.06.2020 | ETheRNA nabs €34M for mRNA vaccines—including COVID-19 candidate W h i t e p a p e r Weighing the Costs: | Belgium’s eTheRNA picked up €34 million ($38 million) to bankroll the development of its mRNA technologies as well as a suite of mRNA immunotherapies for cancer and infectious diseases, including a program against SARS-CoV-2, the virus that... |